There have been many advancements in terms of treatment and imaging modalities for patients with oligometastatic prostate cancer. Failure to understand these advancements in treatment options leads to lower quality of care delivered by clinicians treating prostate cancer patients.

The use of SABR is well established in many cancers, however, its application within kidney cancer is relatively new. This is largely due to the historical notion that renal cell carcinoma (RCC) is highly radioresistant.

This activity discusses the use of PSMA PET for staging in high-risk prostate cancer. This includes when to order a PSMA PET, how to interpret it, common pitfalls and controversies of the scans.

Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or